Details

Autor(en) / Beteiligte

• Merino, Paloma
• Guinea, Jesús
• Muñoz-Gallego, Irene
• González-Donapetry, Patricia
• Galán, Juan Carlos
• Antona, Nerea
• Cilla, Gustavo
• Hernáez-Crespo, Silvia
• Díaz-de Tuesta, José Luis
• Gual-de Torrella, Ana
• González-Romo, Fernando
• Escribano, Pilar
• Sánchez-Castellano, Miguel Ángel
• Sota-Busselo, Mercedes
• Delgado-Iribarren, Alberto
• García, Julio
• Cantón, Rafael
• Muñoz, Patricia
• Folgueira, María Dolores
• Cuenca-Estrella, Manuel
• Oteo-Iglesias, Jesús
• Medrano, Sara
• Pérez, Alba
• Galar, Alicia
• Martínez-Expósito, Oscar
• Alejo-Cancho, Izaskun
• Martín-Higuera, M. Carmen
• Rolo, Marta
• Estévez, M. Jesús
• Bravo, Tania
• Vicente, Diego
• Montes, Mila

Titel

Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection

Ist Teil von

• Clinical microbiology and infection, 2021-05, Vol.27 (5), p.758-761

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The standard RT-PCR assay for coronavirus disease 2019 (COVID-19) is laborious and time-consuming, limiting testing availability. Rapid antigen-detection tests are faster and less expensive; however, the reliability of these tests must be validated before they can be used widely. The objective of this study was to determine the performance of the Panbio™ COVID-19 Ag Rapid Test Device (PanbioRT) (Abbott) in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in nasopharyngeal swab specimens. This prospective multicentre study was carried out in ten Spanish university hospitals and included individuals with clinical symptoms or epidemiological criteria of COVID-19. Only individuals with ≤7 days from the onset of symptoms or from exposure to a confirmed case of COVID-19 were included. Two nasopharyngeal samples were taken to perform the PanbioRT as a point-of-care test and a diagnostic RT-PCR test. Among the 958 patients studied, 325 (90.5%) had true-positive results. The overall sensitivity and specificity for the PanbioRT were 90.5% (95%CI 87.5–93.6) and 98.8% (95%CI 98–99.7), respectively. Sensitivity in participants who had a threshold cycle (CT) < 25 for the RT-PCR test was 99.5% (95%CI 98.4–100), and in participants with ≤5 days of the clinical course it was 91.8% (95%CI 88.8–94.8). Agreement between techniques was 95.7% (κ score 0.90; 95%CI 0.88–0.93). The PanbioRT performs well clinically, with even more reliable results for patients with a shorter clinical course of the disease or a higher viral load. The results must be interpreted based on the local epidemiological context.